Gynecologic and Obstetric Investigation · 2019 · 50 citations · 18 references
MedicineGynecologyOncologyCancer EpidemiologyClinical EpidemiologyGynecologic OncologyCancer MortalityCancer RiskCancer Survival AnalysisEndometrial CancerGynecologic Cancer EpidemiologyMalignant NeoplasmsBaseline Risk DifferencesBaseline Risk StratificationCancer Recurrence RiskCox RegressionEndometrial Cancer Risk StratificationOverall MortalityOverall Survival After Recurrence
AIMS: To compare baseline risk factors for type 1 vs. 2 endometrial cancers and analyze these risk factors for association with overall survival and time to recurrence. METHODS: Retrospective review of 816 consecutive endometrial cancer cases was conducted with diagnosis from January 2005 to December 2010 and clinical course until 2016. Risk factors, treatment, recurrence, and death were compared using 2 sample t tests, χ2 test and Cox Regression models. RESULTS: There were 550 cases of type 1 and 266 cases of type 2 cancer. Patients with type 2 disease were older (p < 0.001), less obese (p = 0.03), non-white (p < 0.001), and menopausal (p = 0.02). There was no difference in use of oral contraceptives, hormone replacement therapy (HRT), smoking, or major cardiovascular disease. Cox Regression models showed that type 2 disease (p < 0.001) and advanced stage (p = 0.001) were associated with recurrence. CONCLUSIONS: Consistent with previous literature, our analysis found that type 2 cancer is more common in non-white, older, and less obese patients and associated with higher mortality and recurrence. However, inconsistent with previous literature, we found no association between type 2 cancer and diabetes mellitus or use of HRT. These factors should be considered when approaching patients with endometrial cancer.
18
Two pathogenetic types of endometrial carcinoma
Jan V. Bokhman · Gynecologic Oncology · 1983 · 2.5K citations
Medicine, Gynecology, Oncology +13
Uterine Papillary Serous Carcinoma: Patterns of Metastatic Spread
Barbara A. Goff, Daniel T. Kato, Rodney A. Schmidt et al. · Gynecologic Oncology · 1994 · 389 citations